Clinical Trials for Mesothelioma Patients: Dasatinib (NSC #732517) Contact Information

Read more here to obtain contact information for the facilities participating in the current clinical trial being conducted to study the effects of Dasatinib (NSC #732517) for patients who have been diagnosed with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only.

Contact information and Locations:
Delaware: CCOP - Christiana Care Health Services; 302-733-6227 or Tunnell Cancer Center; 302-645-3171
Washington, D.C.: Lombardi Comprehensive Cancer Center; 202-444-0381
Florida: Florida Hospital Cancer Institute; 407-303-5623
Illinois: University of Chicago Cancer Research; 773-834-7424
Indiana: Fort Wayne Medical Oncology and Hematology; 260-484-8830
Maryland: Harry & Jeanette Weinberg Cancer Institute at Franklin Square Hospital Center; 443-777-7364 or Union Hospital Cancer Program: 410-398-4000
Missouri: Arch Medical Services, Incorporated at Center for Cancer Care and Research; 314-628-1210 or Missouri Baptist Cancer Center; 314-996-5569
Nebraska: Methodist Estabrook Cancer Center; 402-354-5890
New Jersey: Cancer Institute of New Jersey at Coopers; 856-325-6757
New York: SUNY Upstate Medical University Hospital; 315-464-5476
North Carolina: Kinston Medical Specialists; 252-559-2200 ext. 201 or Wayne Memorial Hospital;
919-580-0000
Ohio: OSU Comprehensive Cancer Center; 614-293-4976
Virginia: Danville Regional Medical Center; 434-799-3753

Courtesy of ClinicalTrials.gov, a service of the U.S. National Institutes of Health

Other helpful links:

Asbestos Asbestos
Asbestos and lung cancer Asbestos and lung cancer
Mesothelioma attorney Mesothelioma attorney
Mesothelioma Lawyer Mesothelioma lawyer
Asbestos attorney Asbestos attorney